Royalty Pharma PLC (RPRX) News

Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will...

Royalty Pharma Declares Fourth Quarter 2024 Dividend

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has...

Form 8-K - Current report

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

NEW YORK and COPENHAGEN, Denmark, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and...

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

COPENHAGEN, Denmark and NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) and...

Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Royalty Pharma Reports Second Quarter 2024 Results

Portfolio Receipts growth of 12% to $608 million; Royalty Receipts growth of 11%Net cash provided by operating...

Form 8-K - Current report

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment...